Mechanistic Insights into the Synergistic Effects of SGLT-2 Inhibitors and ACE Inhibitors/ARBs: Implications for Cardiovascular and Renal Protection in Type 2 Diabetes Mellitus and Beyond

Dear Editor, Recent advancements in type 2 diabetes mellitus (T2DM) management have introduced sodium-glucose cotransporter-2 (SGLT-2) inhibitors alongside established therapies such as angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). This letter highlights the potential benefits of combining SGLT-2 inhibitors with ACEI/ARBs, not only for T2DM but also for cardiovascular and renal protection in diverse patient groups. SGLT-2 inhibitors lower blood glucose by inhibiting glucose reabsorption in the kidneys, while ACEI and ARBs manage hypertension and protect against renal and cardiovascular damage by inhibiting the renin-angiotensin-aldosterone system (RAAS). The combined use of these drug classes offers synergistic benefits beyond glycemic control, particularly in cardiovascular and renal protection.[1] A key mechanism involves their combined effect on glomerular hemodynamics. SGLT-2 inhibitors enhance sodium delivery to the macula densa, leading to afferent arteriolar constriction and mitigating local glomerular hypertension caused by angiotensin II. This complements the vasodilatory effects of ACEI and ARBs, collectively reducing oxidative stress and inflammation, improving renal outcomes and cardiovascular health, and enhancing insulin sensitivity.[1] We identify six clinical conditions where this combination shows significant promise: T2DM with hypertension T2DM with microalbuminuria T2DM with chronic kidney disease T2DM with heart failure Non-diabetic kidney disease Non-diabetic heart failure For patients with T2DM and hypertension, the combination not only enhances blood pressure control but also reduces cardiovascular risk through mechanisms that protect blood vessels.[2] In T2DM with microalbuminuria, this combination addresses albuminuria by impacting multiple pathways, including RAAS and intraglomerular pressure regulation, offering robust renal protection and reducing cardiovascular complications.[3] In T2DM patients with chronic kidney disease, combined therapy slows disease progression by targeting inflammatory processes, oxidative stress, and fibrotic changes. This comprehensive strategy extends its benefits to patients with non-diabetic kidney disease, offering similar protection and disease progression retardation across various renal pathologies.[4] For heart failure management, SGLT-2 inhibitors combined with ACEI/ARBs alleviate symptoms, reduce hospitalizations, and improve overall cardiac health in both diabetic and non-diabetic populations. This demonstrates the efficacy of these drugs in addressing heart failure comprehensively.[5] We advocate for the development of a fixed drug combination of SGLT-2 inhibitors and ACEI/ARBs, particularly in essential hypertension. Preclinical testing in hypertension models is recommended to validate this approach. Such combination therapy has the potential to significantly reduce blood pressure and associated complications, offering a cardio-renal protective strategy. In conclusion, combining SGLT-2 inhibitors with ACEI/ARBs can optimize cardiovascular and renal outcomes, enhancing patient care in both diabetic and non-diabetic settings. This synergistic approach can lead to improved patient outcomes and quality of life by addressing a broad spectrum of conditions beyond glycemic control. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.